alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<TABLE> <S> <C>

<ARTICLE> 5
       
<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-28-1997
<PERIOD-START>                             DEC-30-1996
<PERIOD-END>                               SEP-28-1997
<CASH>                                         218,000
<SECURITIES>                                         0
<RECEIVABLES>                                1,144,000
<ALLOWANCES>                                    35,000
<INVENTORY>                                  2,257,000
<CURRENT-ASSETS>                             8,438,000
<PP&E>                                     120,302,000
<DEPRECIATION>                              27,874,000
<TOTAL-ASSETS>                             146,250,000
<CURRENT-LIABILITIES>                       11,887,000
<BONDS>                                      9,237,000
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                       157,000
<OTHER-SE>                                 111,449,000
<TOTAL-LIABILITY-AND-EQUITY>               146,250,000
<SALES>                                     99,171,000
<TOTAL-REVENUES>                            99,438,000
<CGS>                                       30,607,000
<TOTAL-COSTS>                               57,780,000
<OTHER-EXPENSES>                            32,630,000
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                             772,000
<INCOME-PRETAX>                              3,167,000
<INCOME-TAX>                                 1,172,000
<INCOME-CONTINUING>                          1,995,000
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                 1,995,000
<EPS-PRIMARY>                                      .13
<EPS-DILUTED>                                      .13
        

</TABLE>
Editorial Note on Part 870
Editorial Note: Nomenclature changes to part 870 appear at 73 FR 35341, June 23, 2008.

§ 870.3610 Implantable pacemaker pulse generator. ( a ) *Identification.* An implantable pacemaker pulse generator is a device that has a power supply and electronic circuits that produce a periodic electrical pulse to stimulate the heart. This device is used as a substitute for the heart's intrinsic pacing system to correct both intermittent and continuous cardiac rhythm disorders. This device may include triggered, inhibited, and asynchronous modes and is implanted in the human body.
( b ) *Classification.* Class III (premarket approval).
( c ) *Date PMA or notice of completion of PDP is required.* A PMA or notice of completion of a PDP is required to be filed with the Food and Drug Administration on or before September 20, 2012, for any implantable pacemaker pulse generator device that was in commercial distribution before May 28, 1976, or that has, on or before September 20, 2012, been found to be substantially equivalent to any implantable pacemaker pulse generator device that was in commercial distribution before May 28, 1976. Any other implantable pacemaker pulse generator device shall have an approved PMA or declared completed PDP in effect before being placed in commercial distribution.
[45 FR 7907, Feb. 5, 1980, as amended at 52 FR 17736, May 11, 1987; 77 FR 37576, June 22, 2012]
<TABLE> <S> <C>

<ARTICLE> 5
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          DEC-31-1999
<PERIOD-END>                               MAR-31-1999
<CASH>                                             796
<SECURITIES>                                     7,850
<RECEIVABLES>                                        0
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                                 8,646
<PP&E>                                          43,408
<DEPRECIATION>                                  12,105
<TOTAL-ASSETS>                                  39,949
<CURRENT-LIABILITIES>                          643,217
<BONDS>                                              0
<PREFERRED-MANDATORY>                          768,619
<PREFERRED>                                          0
<COMMON>                                    21,297,570
<OTHER-SE>                                (22,669,457)
<TOTAL-LIABILITY-AND-EQUITY>                    39,949
<SALES>                                              0
<TOTAL-REVENUES>                                     0
<CGS>                                                0
<TOTAL-COSTS>                                    3,203
<OTHER-EXPENSES>                              (72,055)
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                                 68,852
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                                  0
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                    68,852
<EPS-PRIMARY>                                   (0.01)
<EPS-DILUTED>                                   (0.01)
        

</TABLE>
<PAGE>   1
                                                                   EXHIBIT 10.15


                                 DESCRIPTION OF
                SEAMED NON-EMPLOYEE DIRECTOR STOCK OPTION POLICY

      During fiscal year 1998 the Board of Directors of SeaMED Corporation (the
"Board") adopted a director compensation policy which allows the Board to grant
non-qualified stock options to non-employee directors upon their election and
qualification to the Board. Pursuant to such policy, the Board may grant an
option to purchase up to 22,500 shares of Common Stock of the Company to each
non-employee director each time such director is elected to serve a three-year
term on the Board. Unless otherwise determined by the Board or the Board's
Compensation Committee, each such option shall be exercisable for a period of
six years from the date of grant and shall vest at the rate of one-third upon
each of the first, second and third anniversaries of the grant date.
UN PUBLISHED
UNITED STATES COURT OF APPEALS FOR THE FOURTH CIRCUIT

No. 21
- 1065

KRISTINA MERLE LARSON , Plaintiff

- Appellant ,

v. AMERICAN HOME PRODUCTS, WYETH

- AYERST LABORATORIES , Defendant

- Appellee

.

Appeal from the United States District Court for the Eastern District of Virginia , at Norfolk

. Raymond A. Jackson , District Judge. ( 2:19

- cv - 00685

- RAJ

- LRL )

Submitted : June 17, 2021 Decided: August 19, 2021

Before WYNN, THACKER, and RUSHING , Circuit Judges.

Affirmed by un published per curiam opinion

. Kristina Merle Larson, Appellant Pro Se. Milena Radovic, Kristina H. Vaquera, JACKSON LEWIS PC, Norfolk, Virginia, for Appellee.
Unpublished opinions are not binding precedent in this ci rcuit.2 PER CURIAM: Kristina Merle Larson appeals the district court’s order dismissing her complaint in which she alleg ed violations of the Americans with Disabilities Act, 42 U.S.C. §§ 12102

- 12213 , and related claims. We have reviewed the record and fin d no reversible error. Accordingly, we affirm for the reasons stated by the district court. Larson v

. Am

. Home Prods. , No. 2:19

- cv - 00685

- RAJ

- LRL (E.D. Va. Dec. 28, 2020) . We dispense with oral argument because the facts and legal contentions are adequat ely presented in the materials before this court and argument would not aid the decisional process.
AFFIRMED
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### National Institutes of Health

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:*                         National Institute of Nursing Research Initial Review Group.                    

*Date:*                         February 18-19, 2010.                    

*Time:*                         8 a.m. to 12 p.m.                    

*Agenda:*                         To review and evaluate grant applications.                    

*Place:*                         Bethesda Marriott Suites, 6711 Democracy Boulevard, Bethesda, MD 20817.                     

*Contact Person:*                         Weiqun Li, MD, Scientific Review Officer, National Institute of Nursing Research, National Institutes of Health, 6701 Democracy Blvd., Ste. 710, Bethesda, MD 20892, (301) 594-5966,                         *wli@mail.nih.gov.*

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

(Catalogue of Federal Domestic Assistance Program Nos. 93.361, Nursing Research, National Institutes of Health, HHS)

Dated: January 6, 2010.

Jennifer Spaeth,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 2010-429 Filed 1-12-10; 8:45 am]

BILLING CODE 4140-01-P
Exhibit 10.11  


November 20,
2002 


Mr. L
C Greenwood

329 S. Dallas Avenue

Pittsburgh, Pennsylvania 15208 



	Re:
	Nomination to Board of Directors




Dear
Mr. Greenwood: 


        On
behalf of MTR Gaming Group, Inc., I am pleased to let you know that the board of directors, with the concurrence of our Compliance Committee, has nominated you to serve as an
independent member of the board and the board's Compensation Committee. 


        Your
compensation for service on the board will be $24,000 annually (pro rated for any period of service that is less than one full year) and $1,500 for each regular meeting of the board
of directors, compliance committee, or shareholders you attend. The Company will also reimburse you for out-of-pocket expenses you incur in attending such meetings. 


        If
these terms are acceptable to you, please sign where indicated below and return this letter to me. By your signature, you also acknowledge your receipt of and agreement to comply with
the Company's policy concerning conflicts of interest, a copy of which accompanies this letter. 


        We
look forward to your joining the Company. 



	 	 	Very truly yours,
	

 	
 	

/s/  EDSON R. ARNEAULT      
 Edson R. Arneault

President and Chairman of the Board
	

AGREED AND ACCEPTED:	
 	

 
	

/s/  LC GREENWOOD      
 L C Greenwood
Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of ViroPharma Incorporated (the Company) on Form
10-K for the period ending December 31, 2007 as filed with the Securities and Exchange Commission on the date hereof (the Report), each of the undersigned officers of the Company, certify, pursuant to 18 U.S.C. § 1350, as
adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:



| | (1) | The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
| | --- | ---------------------------------------------------------------------------------------------------------------------



| | (2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
| | --- | ----------------------------------------------------------------------------------------------------------------------------------------------------



|                                                                         
|-------------------------------------------------------------------------
|/s/ Michel de Rosen                                                      
|Michel de Rosen                                                          
|President, Chief Executive Officer and Chairman of the Board of Directors
|February 26, 2008                                                        



|                                                                              
|------------------------------------------------------------------------------
|/s/ Vincent J. Milano                                                         
|Vincent J. Milano                                                             
|Vice President, Chief Operating Officer, Chief Financial Officer and Treasurer
|February 26, 2008
SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549

                                   ----------

                                    FORM 8-K

                                 CURRENT REPORT
                     Pursuant to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 16, 2003

                           Vermont Pure Holdings, Ltd.
               --------------------------------------------------
               (Exact Name of Registrant as Specified in Charter)

          Delaware                   000-31797                 03-0366218
          --------                   ---------                 ----------
(State or other jurisdiction        (Commission              (IRS Employer
      of incorporation)             File Number)         Identification Number)

    P.O. Box C, Route 66, Catamount Industrial Park, Randolph, Vermont 05060
    -------------------------------------------------------------------------
               (Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code (802) 728-3600

                                       n/a
          -------------------------------------------------------------
          (Former Name or Former Address, if Changed Since Last Report)


<PAGE>

ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS

      (c) Exhibits

        Number                          Title
        ------                          -----

         99.1            Press Release dated June 16, 2003

ITEM 12. RESULTS OF OPERATIONS AND FINANCIAL CONDITION

      On June 16, 2003, Vermont Pure Holdings, Ltd. issued the press release
attached as Exhibit 99.1 to this Current Report on Form 8-K.

                                   SIGNATURES

      Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.

                                        Vermont Pure Holdings, Ltd.

                                        By: /s/ Bruce S. MacDonald
                                            -------------------------
                                            Bruce S. MacDonald
                                            Chief Financial Officer

Date: June 16, 2003


<PAGE>

                                 EXHIBIT INDEX

Number                                  Title
------                                  -----

99.1                     Press Release dated June 16, 2003
<TABLE> <S> <C>


<ARTICLE>                     5

<MULTIPLIER>                  1
<CURRENCY>                    U.S. Dollars

<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>               SEP-30-1999
<PERIOD-START>                  OCT-01-1998
<PERIOD-END>                    JUN-30-1999
<EXCHANGE-RATE>                            1
<CASH>                               147,425
<SECURITIES>                               0
<RECEIVABLES>                         18,450
<ALLOWANCES>                               0
<INVENTORY>                                0
<CURRENT-ASSETS>                     165,875
<PP&E>                               304,914
<DEPRECIATION>                       134,122
<TOTAL-ASSETS>                       336,367
<CURRENT-LIABILITIES>                 64,770
<BONDS>                                    0
<PREFERRED-MANDATORY>                      0
<PREFERRED>                                0
<COMMON>                             122,146
<OTHER-SE>                           133,126
<TOTAL-LIABILITY-AND-EQUITY>         336,667
<SALES>                                    0
<TOTAL-REVENUES>                       3,000
<CGS>                                      0
<TOTAL-COSTS>                         19,305
<OTHER-EXPENSES>                           0
<LOSS-PROVISION>                           0
<INTEREST-EXPENSE>                        45
<INCOME-PRETAX>                      (10,350)
<INCOME-TAX>                               0
<INCOME-CONTINUING>                  (10,350)
<DISCONTINUED>                       (16,834)
<EXTRAORDINARY>                            0
<CHANGES>                                  0
<NET-INCOME>                         (27,184)
<EPS-BASIC>                            .00
<EPS-DILUTED>                            .00



</TABLE>
<TABLE> <S> <C>

<ARTICLE> 5
<CIK> 0000814070
<NAME> DRY DAIRY INTERNATIONAL, INC.
       
<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-1996
<PERIOD-END>                               SEP-30-1996
<CASH>                                          50,720
<SECURITIES>                                         0
<RECEIVABLES>                                   20,542
<ALLOWANCES>                                         0
<INVENTORY>                                     87,462
<CURRENT-ASSETS>                               169,033
<PP&E>                                          86,843
<DEPRECIATION>                                       0
<TOTAL-ASSETS>                                 255,876
<CURRENT-LIABILITIES>                          225,270
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                     1,533,726
<OTHER-SE>                                 (1,511,575)
<TOTAL-LIABILITY-AND-EQUITY>                   255,876
<SALES>                                        262,794
<TOTAL-REVENUES>                               262,794
<CGS>                                          211,555
<TOTAL-COSTS>                                  316,259
<OTHER-EXPENSES>                             (108,301)
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                              11,685
<INCOME-PRETAX>                              (168,404)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                                  0
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                 (168,404)
<EPS-PRIMARY>                                   (0.01)
<EPS-DILUTED>                                   (0.01)
        

</TABLE>
Editorial Note on Part 866
Editorial Note: Nomenclature changes to part 866 appear at 73 FR 35341, June 23, 2008.

§ 866.5430 *Beta*-2-glycoprotein I immunological test system. ( a ) *Identification.* A *beta*-2-glycoprotein I immunological test system is a device that consists of the reagents used to measure by immunochemical techniques the *beta*-2-glycoprotein I (a serum protein) in serum and other body fluids. Measurement of *beta*-2-glycoprotein I aids in the diagnosis of an inherited deficiency of this serum protein.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 866.9.
[47 FR 50823, Nov. 9, 1982, as amended at 65 FR 2312, Jan. 14, 2000]
Exhibit No. 11


                                   CNS, INC.

              Computation of Net Income per Share of Common Stock
<TABLE>
<CAPTION>

                                                  Three Months Ended  March 31,
                                                --------------------------------
                                                     1998              1997
                                                --------------     -------------
NET INCOME                                                        
<S>                                               <C>               <C>        
 Net income                                       $    15,288       $ 1,321,493
                                                  ===========       ===========
                                                                    
                                                                    
BASIC NET INCOME PER SHARE                                          
 Weighted average number of common                                  
   shares outstanding                              18,374,000        19,205,000
                                                  ===========       ===========
                                                                    
 Basic net income per share                       $       .00       $       .07
                                                  ===========       ===========
                                                                    
                                                                    
                                                                    
DILUTED NET INCOME PER SHARE                                        
  Weighted average number of common                                 
    shares outstanding                             18,374,000        19,205,000
  Incentive stock options                             205,000           520,000
  Non qualified stock options                         173,000           319,000
                                                  -----------       -----------
 Weighted average number of common and                              
   assumed conversion shares                       18,752,000        20,044,000
                                                  ===========       ===========
                                                                    
 Diluted net income per share                     $       .00       $       .07
                                                  ===========       ===========
                                                                  

</TABLE>
#### Ann Fedak *v.*Joseph Woichowski et al., Executors (Estate of Walter M. Wojkowsky)

The motions by the plaintiff to dismiss the appeal from the Superior Court in Fairfield County are denied.

*609
      *Raphael Korff,*for the appellee (plaintiff).

*Leonard C. Blum,*for the appellants (defendants).

Argued November 5

decided November 6, 1968